New program aims to ease joint pain for breast cancer patients on hormone therapy

NCT ID NCT07500038

Completed Symptom relief Sponsor: Yuling CAO Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested a culturally adapted program to help breast cancer patients manage joint and muscle pain caused by hormone therapy. 289 women on aromatase inhibitors received either the tailored program (health education, monitoring, and nursing guidance) or standard care. Researchers measured changes in joint function and how well the program was adopted in real-world clinics.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Culturally Adapted EBP Program (behavioral intervention: health education, monitoring, nursing guidance)
What this could lead to: If it works, this could provide a practical, culturally sensitive way to help breast cancer patients manage joint pain and stiffness caused by hormone therapy.
What could go wrong: This is a completed implementation study, not a treatment trial. The program may not reduce symptoms significantly more than standard care, and results may not apply to all cultural groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AROMATASE INHIBITOR ASSOCIATED MUSCULOSKELETAL SYMPTOMS (AIMSS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AROMATASE INHIBITOR ASSOCIATED MUSCULOSKELETAL SYMPTOMS (AIMSS) BREAST NEOPLASMS

Contacts and locations

Locations

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.